Skip to main content
OpenTrials
Completed

NCT Number: NCT00762970

Controlling Myopia Progression With Soft Contact Lenses

This study is to investigate whether novel soft contact lens optical designs can slow myopia progression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Tianjin Eye Hospital

Tianjin, 300020, China

About this study

The study will be a prospective, randomized, single blind, bilateral dispensing study

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Myopic subjects between 8 and 12 years of age.
  • The subject best sphere contact lens correction must lie between -0.75D (best of the two eyes) and -5.00D (worst of the two eyes)
  • Astigmatism must be less than or equal to 1.00D
  • 1.00D or less difference in spherical equivalent between the two eyes
  • The subject must have a best-corrected visual acuity of 0.8+2 (20/25+2) and spherical equivalent refraction visual acuity of 0.820/25) or better in both eyes
  • The subject must have at least 8D of accommodation
  • The subject and subject's parent or legal guardian must read and sign the STAEMENT OF INFORMED CONSENT
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.

Exclusion criteria

  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Systemic disease or autoimmune disease or use of medication (e.g. antihistamine), which may interfere with lens wear.
  • Clinically significant (grade 3 or 4)corneal edema, corneal vascularization, corneal staining, or any other abnormality of the cornea, which may contraindicate contact lens wear.
  • Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection that might interfere with contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Any infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g. HIV)
  • Diabetes
  • Anisometropia of greater than 1.00D
  • Astigmatism of greater than 1.00D in either eye
  • Eye injury or surgery within eight weeks immediately prior to enrollment for this study.
  • Pervious refractive surgery, rigi contact lens wear, orthokeratology, keratconus or other corneal irregularity in either eye.
  • Strabismus in either eye
  • Pupil orr lid abnormality or infection in either eye
  • Central corneal scar in either eye
  • Aphakia in either eye
  • Contraindications to contact lens wear such as dry eye or history of prior unsuccessful contact lens wear.
  • History of participation in prior clinical trials aimed to control myopia progression
  • Surgically altered eyes, ocular infection of any type, ocular inflammation
  • Subject has anterior chamber angle grade 2 or narrower

Treatment and study plan

Test Lens 1

Device

Investigational soft contact lens with asperic optical design to control myopia progression.

Test Lens 2

Device

Investigational soft contact lens with asperic optical design to control myopia progression.

Control lens

Device

Spectacle Lenses.

Primary outcomes

  1. Spherical Equivalent Refraction

    Time frame: Baseline and every 6 months post-baseline for 2 years

    Spherical equivalent refraction was computed from the sphero-cylindrical refraction measured with an open-field auto refractor (WAM-5500) and descriptively summarized for each follow-up. Higher spherical refraction indicates progression in Myopia.

  2. Axial Length (Axial Elongation)

    Time frame: Baseline and every 6 months post-baseline for 2 years

    Axial length was measured with the IOLMaster at baseline and every 6 months post-baseline for 2 years. Axial length was descriptively summarized for each follow-up.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Vision Care, Inc.

Industry

Registry information

Important dates

Study start
2007
Primary completion
2010
Study completion
2010
First posted
Sep 30, 2008
Registry last updated
Jun 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.